BiogenBIIBEarnings & Financial Report
Nasdaq · Health Care · Biotechnology
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| The Vanguard Group | 11.44% | 16.7M | flat | 2024-11-12 |
| PRIMECAP Management Company | 11.22% | 16.3M | — | 2024-02-12 |
| BlackRock, Inc. | 10.10% | 14.6M | ▲ +0.30pp | 2024-08-07 |
| STATE STREET CORPORATION | 5.00% | 7.3M | — | 2024-10-16 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | Sean Godbout | Chief Accounting Officer | Option exercise | 181 | $0.00 | $0 |
1–1 of 1